Last reviewed · How we verify

IPX203 — Competitive Intelligence Brief

IPX203 (IPX203) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid analgesic with abuse-deterrent properties. Area: Pain Management.

phase 3 Opioid analgesic with abuse-deterrent properties Mu opioid receptor (morphine component); opioid receptors (naltrexone component) Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

IPX203 (IPX203) — Impax Laboratories, LLC. IPX203 is an extended-release combination of morphine and naltrexone designed to provide opioid analgesia while reducing the potential for abuse and addiction.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
IPX203 TARGET IPX203 Impax Laboratories, LLC phase 3 Opioid analgesic with abuse-deterrent properties Mu opioid receptor (morphine component); opioid receptors (naltrexone component)
Oxycodone/Naltrexone Capsules Oxycodone/Naltrexone Capsules Elite Laboratories, Inc phase 3 opioid analgesic with abuse-deterrent properties mu-opioid receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid analgesic with abuse-deterrent properties class)

  1. Impax Laboratories, LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IPX203 — Competitive Intelligence Brief. https://druglandscape.com/ci/ipx203. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: